NIH spinout raises millions to attack drug-resistant cancers with RNA. It has big plans.

Published on :

Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.